
64.66 Delayed Data As of May 26 | ![]() Today’s Change | 38.94 Today|||52-Week Range 86.95 | +59.07% Year-to-Date |
The 26 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 71.00, with a high estimate of 220.00 and a low estimate of 42.00. The median estimate represents a +9.81% increase from the last price of 64.66.
The current consensus among 30 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.